KRAS and cancer: UGCG and B4GALT5, which encodes LCS, were significantly elevated in KRAS mutant cancers (n = ~730) (Figs. 5a, b and S7a), and combined high expression of UGCG and B4GALT5 correlated with shortened 5-year survival (Fig. 5c).